{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:40:37Z","timestamp":1759473637152,"version":"build-2065373602"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,2]]},"DOI":"10.7759\/cureus.93748","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:10:41Z","timestamp":1759471841000},"source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic Body Radiation Therapy Without Androgen Deprivation in a 92-Year-Old With Oligometastatic Stage IVA Prostate Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Pericles J","family":"Ioannides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane A","family":"Tipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg A","family":"Weidlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile SG","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al.. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018, 36:2326-47. 10.1200\/JCO.2018.78.8687","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018, 392:2353-66. 10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips R","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al.. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020, 6:650-9. 10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma DA","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020, 38:2830-8. 10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree AC","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, et al.. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022, 23:1308-20. 10.1016\/S1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.053","article-title":"Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: systematic review and meta-analysis","volume":"118","author":"Mohamad O","year":"2024","unstructured":"Mohamad O, Zamboglou C, Zilli T, et al.. Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2024, 118:998-1010. 10.1016\/j.ijrobp.2023.09.053","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-016-1040-6","article-title":"Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer","volume":"193","author":"Pinkawa M","year":"2017","unstructured":"Pinkawa M, Berneking V, K\u00f6nig L, Frank D, Bretgeld M, Eble MJ. Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017, 193:22-8. 10.1007\/s00066-016-1040-6","journal-title":"Strahlenther Onkol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani AB","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, et al.. (18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial. Lancet. 2021, 397:1895-904. 10.1016\/S0140-6736(21)00581-X","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.201749","article-title":"(68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais J","year":"2018","unstructured":"Calais J, Czernin J, Cao M, et al.. (68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018, 59:230-7. 10.2967\/jnumed.117.201749","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark A","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019, 394:385-395. 10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.935310","article-title":"High dose \"HDR-Like\" prostate SBRT: PSA 10-year results from a mature, multi-institutional clinical trial","volume":"12","author":"Fuller DB","year":"2022","unstructured":"Fuller DB, Crabtree T, Kane BL, et al.. High dose \"HDR-Like\" prostate SBRT: PSA 10-year results from a mature, multi-institutional clinical trial. Front Oncol. 2022, 12:935310. 10.3389\/fonc.2022.935310","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1302001","article-title":"Retrospective study on the toxicity induced by stereotactic body radiotherapy: overview of the reunion experience on prostate cancer in elderly patients","volume":"14","author":"Slama Y","year":"2024","unstructured":"Slama Y, Baumont G, Arcambal A, et al.. Retrospective study on the toxicity induced by stereotactic body radiotherapy: overview of the reunion experience on prostate cancer in elderly patients. Front Oncol. 2024, 14:1302001. 10.3389\/fonc.2024.1302001","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/382564-stereotactic-body-radiation-therapy-without-androgen-deprivation-in-a-92-year-old-with-oligometastatic-stage-iva-prostate-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:10:42Z","timestamp":1759471842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/382564-stereotactic-body-radiation-therapy-without-androgen-deprivation-in-a-92-year-old-with-oligometastatic-stage-iva-prostate-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.93748","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}